Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: A potential animal model of emotional context processing in Schizophrenia?

Schizophrenia Bulletin

Volumn 35, Issue 4, 2009, Pages 748-759

  Calzavara, Mariana Bendlin ^a   Medrano, Wladimir Agostini ^a   Levin, Raquel ^a   Kameda, Sonia Regina ^a   Andersen, Monica Levy ^a   Tufik, Sergio ^a   Silva, Regina Helena ^b   Frussa Filho, Roberto ^a   Abílio, Vanessa Costhek ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Amphetamine; Antipsychotics; Emotional memory; Mood stabilizers; Psychiatric disorder; Rats

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMISULPRIDE; AMPHETAMINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOZAPINE; HALOPERIDOL; KETAMINE; LAMOTRIGINE; METHYLPHENIDATE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PENTETRAZOLE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; DOPAMINE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; EMOTION; FEAR; LATENT INHIBITION; MALE; MENTAL DISEASE; MENTAL TASK; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; REM SLEEP DEPRIVATION; SCHIZOPHRENIA; SHOCK; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR RAT; ANIMAL; ANIMAL BEHAVIOR; CATALEPSY; DISEASE MODEL; ELECTRIC SHOCK; INHIBITION (PSYCHOLOGY); MEMORY; PAIN THRESHOLD; PHYSIOLOGY; PSYCHOLOGY; SLEEP DEPRIVATION; VOCALIZATION; WISTAR KYOTO RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; ELECTROSHOCK; EMOTIONS; FEAR; FREEZING REACTION, CATALEPTIC; INHIBITION (PSYCHOLOGY); MALE; MEMORY; PAIN THRESHOLD; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP DEPRIVATION; VOCALIZATION, ANIMAL;

EID: 68149165786     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn006     Document Type: Article

References (80)

1. Darwin C. The Expression of the Emotions in Man and Animals. Chicago Ill: University of Chicago Press 1872.
2. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry. 2003;54:515-528.
3. Marsh PJ, Williams LM. ADHD and schizophrenia phenomenology: visual scanpaths to emotional faces as a potential psychophysiological marker? Neurosci Biobehav Rev. 2006;30:651-665.
4. Addington J, Addington D. Facial affect recognition and information processing in schizophrenia and bipolar disorder. Schizophr Res. 1998;32:171-181.
5. LeDoux JE. Emotion circuits in the brain. Ann Rev Neurosci. 2000;23:155-184.
6. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Progress Neurobiol. 2004;74:301-320.
7. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20. (Pubitemid 41002508)
8. Martin MV, Dong H, Bertchume A, Csernansky JG. Low dose quetiapine reverses deficits in contextual and cued fear conditioning in rats with excitotoxin-induced hippocampal neuropathy. Pharmacol Biochem Behav. 2005;82:263-269.
9. Bardgett ME, Jacobs JL, Taylor GT, Csernansky JG. Kainic acid decreases hippocampal neuronal number and increases dopamine receptor binding in the nucleus accumbens: an animal model of schizophrenia. Behav Brain Res. 1995;70: 153-164.
10. Stubley-Weatherly L, Harding JW, Wright JW. Effects of discrete kainic acid induced hippocampal lesions on spatial and contextual learning and memory in rats. Brain Res. 1996;716:29-38.
11. Yin H, Bardgett ME, Csernansky JG. Kainic acid lesions disrupt fear-mediated memory processing. Neurobiol Learn Mem. 2002;77:389-401.
12. Sagvolden T, Sergeant JA. Attention deficit/hyperactivity dis-order-from brain dysfunctions to behaviour. Behav Brain Res. 1998;94:1-10.
13. RussellVA.Neurobiologyofanimalmodelsofattention-deficit hyperactivity disorder. J Neurosci Methods. 2007;161:185-198.
14. Sagvolden T, Metzger MA, Schiørbeck HK, Rugland AL, Spinnangr I, Sagvolden G. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomo-tor stimulants. Behav Neural Biol. 1992;58:103-112.
15. LeDoux JE, Sakaguchi A, Reis DJ. Strain differences in fear between spontaneously hypertensive and normotensive rats. Brain Res. 1983;277:137-143.
16. Calzavara MB, Patti CL, Lopez GB, Abilio VC, Silva RH, Frussa-Filho R. Role of learning of open arm avoidance in the phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in mice. Life Sci. 2004;76:2235-2246.
17. Calzavara MB, Lopez GB, Abilio VC, Silva RH, Frussa-Filho R. Role of anxiety levels in memory performance of spontaneously hypertensive rats. Behav Pharmacol. 2005;15:545-553.
18. Anseloni VZ, Brandão ML. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze. Behav Pharmacol. 1997;8:533-540
19. Myers MM, Musty RE, Hendley ED. Attenuation of hyper-activity in the spontaneously hypertensive rat by amphetamine. Behav Neural Biol. 1982;34(1):42-54.
20. Yang PB, Swann AC, Dafny N. Acute and chronic methyl-phenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull. 2006;71(1-3):301-310.
21. Arban R, Maraia G, Brackenborough K, et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res. 2005;158:123-132.
22. Lamberty Y, Margineanu DG, Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav. 2001;2:454-459.
23. Feldon J, Weiner I. The latent inhibition model of schizophrenia attention disorder. Haloperidol and sulpiride enhance ratś ability to ignore irrelevant stimuli. Biol Psychiatry. 1991;29:635-646.
24. Abdul-Monim Z, Reynolds GP, Neill JC. The effects of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res. 2006;169:263-273.
25. Weiner I, Schiller D, Gaisler-Salomon I. Disruption and po-tentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology. 2003;28:499-509.
26. SchmittU,Abou El-ElaA,Guo LJ,etal. CyclosporineA(CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm. 2006;113:787-801.
27. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuro-Psy-chopharmacol Biol Psychiatry. 2003;27:687-700.
28. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980;137:801-805.
29. Moser PC, Hitchcock JM, Lister S, Moran PM. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev. 2000;33:275-307.
30. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology. 2003;169:257-297.
31. Machado RB, Hipolide DC, Benedito-Silva AA, Tufik S. Sleep deprivation induced by multiple platform technique: quantification of sleep loss and recovery. Brain Res. 2004;1004:45-51.
32. Frussa-Filho R, Palermo-Neto J. Effects of single and long-term metoclopramide administration on open field and stereotyped behavior of rats. Eur J Pharmacol. 1988;10:323-329.
33. Hess EJ, Norman AB, Creese I. Chronic treatment with do-pamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J Neurosci. 1988;8:2361-2370.
34. Hipólide DC, Tufik S. Paradoxical sleep deprivation in female rats alters drug-induced behaviors. Physiol Behav. 1995;57:1139-1143.
35. Troncone LR, Ferreira TM, Braz S, Silveira Filho NG, Tufik S. Reversal of the increase in apomorphine-induced stereo-typy and aggression in REM sleep deprived rats by dopamine agonist pretreatments. Psychopharmacology. 1988;94:79-83.
36. Tufik S. Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation. Psychopharmacology. 1981;72:257-260.
37. Andersen ML, Tufik S. The effects of dopaminergic agonists on genital reflexes in paradoxical sleep-deprived male rats. Physiol Behav. 2005;84:205-210. (Pubitemid 40222715)
38. Taylor BK, Peterson MA, Basbaum AI. Exaggerated cardiovascular and behavioral nociceptive responses to subcutaneous formalin injection in the spontaneously hypertensive rat. Neurosci Lett. 1995;201:9-12.
39. Taylor BK, Roderick RE, Basbaum AI. Brainstem noradren-ergic control of nociception is abnormal in the spontaneously hypertensive rat. Neurosci Lett. 2000;291:139-142.
40. Taylor BK, Roderick RE, Lezin EST, Basbaum AI. Hypoal-gesia and hyperalgesia with inherited hypertension in the rat. Am J Physiol Regulatory Integrative Comp Physiol. 2001;280:R345-R354.
41. Helmstetter FJ. Stress-induced hypoalgesia and defensive freezing are attenuated by application of diazepam to the amygdale. Pharmacol Biochem Behav. 1993;44:433-438.
42. Graeff FG, Netto FC, Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev. 1998;23:237-246.
43. Gentsch C, Lichtsteiner M, Feer H. Open field and elevated plus-maze: a behavioural comparison between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats and the effects of chlordiazepoxide. Behav Brain Res. 1987;25:101-107.
44. Goto SH, Conceixcão IM, Ribeiro R de A, Frussa-Filho R. Comparison of anxiety measured in the elevated plus-maze, open-field and social interaction tests between spontaneously hypertensive rats and Wistar EPM-1 rats. Braz J Med Biol Res. 1993;26:965-969.
45. Conceixcão IM, Goto SH, Frussa-Filho R. Evaluation of memory in an elevated T maze: a comparison between spontaneously hypertensive, Wistar-Kyoto and Wistar EPM-1 rats. Braz J Med Biol Res. 1994;27:731-735.
46. Ramos A, Kangerski AL, Basso PF, et al. Evaluation of Lewis and SHR rat strain as a genetic model for the study of anxiety and pain. Behav Brain Res. 2002;129:113-123.
47. Van den Bergh FS, Bloemarts E, Chan JSW, Groenink L, Olivier B, Oosting RS. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol Biochem Behav. 2006;83:380-390.
48. Bizot JC, Chenault N, Houze B, et al. Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacology. 2007;193(2):215-223.
49. Inoue T, Tsuchiya K, Koyama T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav. 1996;55:195-201.
50. Inoue T, Izumi T, Maki Y, Muraki I, Koyama T. Effect of the dopamine D1/5 antagonist SCH 23390 on the acquisition of conditioned fear. Pharmacol Biochem Behav. 2000;66: 573-578.
51. de Oliveira AR, Reimer AE, Brandão ML. Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav. 2006;84:102-111.
52. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanes-thetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13:9-19.
53. Bressan RA, Pilowsky BELS. Glutamatergic Hypothesis Of Schizophrenia. Rev Bras Psiquiatr. 2003;25:177-183.
54. Giedke H, Schwarzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev. 2002;6(5):361-377.
55. Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med. 2007;3(5):519-528.
56. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology. 1979;65:73-77.
57. Laruelle M, Abi-Dargham A, Van Dyck CH, et al. Neurobi-ology Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235-9240.
58. Russel V, De Villiers A, Sagvolden T, Lamn M, Taljaard J. Differences between eletrically-, ritalin and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in animal model of Attention-Deficit Hyperactivity Disorder. Behav Brain Res. 1998;94:163-171.
59. Lubow RE. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schiz-ophr Res. 2005;31:139-153.
60. Lubow RE. Latent Inhibition and Conditioned Attention Theory. New York, NY: Cambridge University Press; 1989.
61. Gray NS, Hemsley DR, Gray JA. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatry Brain Res. 1992;1:83-89.
62. Randich A, LoLordo VM. Associative and nonassociative theories of the UCS preexposure phenomenon: implications for Pavlovian conditioning. Psychol Bull. 1979;86:523-548.
63. Chang T, Meyer U, Feldon J, Yee BK. Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psy-chopharmacology. 2007;191:211-221
64. PalmerAA,DulawaSC,MottiwalaAA,Conti LH,Geyer MA, Printz MP. Prepulse startle deficit in the Brown Norway rat: a potential genetic model. Behav Neurosci. 2000;114:374-388.
65. Ferguson SA, Cada AM. Spatial learning/memory and social and nonsocial behaviors in the spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rat strains. Pharmacol Biochem Behav. 2004;77:583-594.
66. Kinkead B, Selz KA, Owens MJ, Mandell AJ. Algorithmi-cally designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism. J Neurosci Methods. 2006;151:68-81.
67. Vendruscolo LF, Terenina-Rigaldie E, Raba F, Ramos A, TakahashiRN,MormedeP.AQTLonratchromosome7mod-ulates prepulse inhibition, a neuro-behavioral trait of ADHD, in a Lewis x SHR intercross. Behav Brain Funct. 2006;2:21.
68. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sen-sorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 2001;156:117-154.
69. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psycho-pharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1411-1419.
70. Gardos G, Cole JO. Neuroleptic-treatment and tardive dyski-nesia. In: Yassa R, Nair PV, Jeste DV, eds. Neuroleptic-Induced Movement Disorders. New York, NY: Cambridge University Press; 1997;104-116.
71. Queiroz CM, Piovezan RD, Frussa-Filho R. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Eur J Pharmacol. 1998;356:105-108.
72. Abilio VC, Silva RH, Carvalho RC, et al. Important role of striatal catalase in aging-and reserpine-induced oral dyskine-sia. Neuropharmacology. 2004;47:263-272.
73. Williams LM, Das P, Liddell BJ, et al. Fronto-limbic and au-tonomic disjunctions to negative emotion distinguish schizophrenia subtypes. Psychiatry Res. 2007;155:29-44.
74. Das P, Kemp AH, Flynn G, et al. Functional disconnections in the direct and indirect amygdala pathways for fear processing in schizophrenia. Schizophr Res. 2007;90:284-294.
75. Williams LM, Das P, Harris AW, et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry. 2004;161:480-489.
76. Hemsley DR. The development of a cognitive model of schizophrenia: placing it in context. Neurosci Biobehav Rev. 2005;29:977-988.
77. Hemsley DR. The schizophrenic experience: taken out of context? Schizophr Bull. 2005;31:43-53.
78. Broadbent DE. Perceptional Communication. London: Perga-mon; 1958.
79. Broadbent DE. Decision and Stress. London: Academic Press; 1971.
80. Aleman A, Kahn RS. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol. 2005;77(5):283-298.